Chemists at Gutenberg University Mainz have found a way how the new corona drug molnupiravir can be manufactured more cheaply.
The drug is supposed to prevent severe courses of Covid-19;
it is not yet approved in Europe.
Together with colleagues from the Massachusetts Institute of Technology and the University of Graz, as well as the Indian pharmaceutical company TCG Life Sciences, the researchers tested two synthesis routes for molnupiravir on a kilogram scale.
They were based on widely available raw materials and could be used by any manufacturer.
The scientists believe that this will increase the availability of the drug around the world.
It could also reduce costs and avoid supply chain difficulties.
The project, led by the Medicines for All Institute at Virginia Commonwealth University, received funding from the Bill & Melinda Gates Foundation.
The link to the study